- cafead Jan 31, 2021 at 10:32: PM
via Coming off a stellar year, when a record 53 new molecular entities were approved, 2021 has a lot to live up to. NMEs are a measure of innovation among biopharma companies, as they refer to drugs containing an active ingredient that has never been approved previously.
Although the calendar for drug approval decisions, known as PDUFA dates, for January was fairly light, most verdicts issued in the month were positive. Among the drugs approved in the month were Merck & Co., Inc.'s (NYSE: MRK) heart failure drug, an expanded indication for Pfizer Inc.'s (NYSE: PFE) lymphoma drug and Aurinia Pharmaceuticals Inc's (NASDAQ: AUPH) kidney inflammation drug.
article source
Although the calendar for drug approval decisions, known as PDUFA dates, for January was fairly light, most verdicts issued in the month were positive. Among the drugs approved in the month were Merck & Co., Inc.'s (NYSE: MRK) heart failure drug, an expanded indication for Pfizer Inc.'s (NYSE: PFE) lymphoma drug and Aurinia Pharmaceuticals Inc's (NASDAQ: AUPH) kidney inflammation drug.
article source